on NANOBIOTIX (EPA:NANO)
NANOBIOTIX Presents New Data at ASCO 2024
NANOBIOTIX, a French biotechnology company, announces the presentation of new data at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting. These data come from the Phase 1 study, titled study 1100, which is evaluating NBTXR3 followed by an anti-PD-1 in patients with recurrent or metastatic head and neck cancer.
Results will be presented by Colette Shen, MD, PhD, and include information on the completed dose escalation portion and the ongoing expansion portion of the study. This presentation will take place on Sunday, June 2, 2024 at 10 a.m. EDT.
Following the presentation at ASCO, Nanobiotix will hold a conference call and webcast at 12 p.m. EDT to discuss the results with investors. Participants will be able to ask questions and view the presentation online, the replay of which will be available on the company's website.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all NANOBIOTIX news